IMO the disconnect is that we are not going to order a billion doses until we have approval. We've placed orders that are sufficient to start with. Once the FDA provides approval, we will scale up the production based on the approval(s) we recieve.

For example, if we initially only receive approval for severe/critical patients, we will need less doses than we will if/when we are approved for mild to moderate. Same logic applies to the demand worldwide.

I believe that (provided we get some sort of approval) we will use the initial batches of leronlimab on the severe population while we continue to build the case that it should be administered earlier in the process.

With that said, money will become readily available and we will scale up.